Vesinac Tablet 5 mg contains Solifenacin Succinate, a well-established antimuscarinic agent used in the management of symptoms associated with overactive bladder (OAB). It is designed to reduce urinary urgency, frequency, and urge incontinence, thereby significantly improving bladder control and enhancing quality of life in affected patients.

Solifenacin Succinate works by selectively blocking muscarinic receptors (primarily M3 receptors) in the bladder detrusor muscle. By inhibiting involuntary bladder contractions during the filling phase, Vesinac Tablet helps increase bladder capacity and decreases episodes of sudden urgency and involuntary urine leakage. Its once-daily oral dosing ensures convenience and better patient adherence to therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Antimuscarinic

• Urinary Antispasmodic

Indications

Vesinac Tablet 5 mg is indicated for the treatment of symptoms of overactive bladder, including:

• Urinary urgency

• Increased urinary frequency

• Urge urinary incontinence

It is suitable for adult patients who experience involuntary bladder contractions leading to bothersome urinary symptoms.

Pharmacology

Solifenacin Succinate is a competitive muscarinic receptor antagonist with selectivity for the M3 receptor subtype. By blocking these receptors in the bladder, it reduces smooth muscle contraction and suppresses detrusor overactivity. Solifenacin is well absorbed after oral administration and undergoes extensive hepatic metabolism, primarily via the CYP3A4 enzyme system. The drug has a long elimination half-life, allowing for once-daily dosing. It is excreted through both renal and fecal pathways.

Dosage and Administration

The usual recommended dose of Vesinac Tablet is 5 mg once daily, taken orally with or without food. Based on clinical response and tolerability, the dose may be adjusted by the physician. Tablets should be swallowed whole with water and not crushed or chewed.

Dose adjustment may be necessary in patients with severe renal impairment or moderate hepatic impairment. Vesinac should be used cautiously in such populations.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Concomitant use with strong CYP3A4 inhibitors (such as ketoconazole or itraconazole) may increase plasma concentrations of Solifenacin and should be monitored carefully. Caution is advised when Vesinac is used alongside other anticholinergic medications, as additive effects may occur.

Contraindications

Vesinac Tablet is contraindicated in patients with:

• Urinary retention

• Gastric retention

• Uncontrolled narrow-angle glaucoma

• Known hypersensitivity to Solifenacin Succinate or any component of the formulation

Side Effects

Vesinac is generally well tolerated. Common side effects may include dry mouth, constipation, blurred vision, nausea, and dizziness. Less commonly, urinary retention, abdominal discomfort, or fatigue may occur. Most adverse effects are mild to moderate and related to the anticholinergic action of the drug.

Precautions and Warnings

Caution should be exercised in patients with bladder outflow obstruction, gastrointestinal obstructive disorders, or decreased gastrointestinal motility. Patients should be advised about possible effects on vision and alertness, especially when initiating therapy.

Pregnancy and Lactation

There are limited data on the use of Solifenacin in pregnant women. Vesinac should be used during pregnancy only if the potential benefit justifies the potential risk. Caution is advised when administering to breastfeeding mothers, as it is not known whether Solifenacin is excreted in human milk.

Storage Conditions

Store in a cool, dry place away from light and moisture. Keep out of the reach of children.